D ecompensation in cirrhosis carries high morbidity, mortality, and poor quality of life (QOL). (1) The only definitive treatment is liver transplantation (LT). However, it is resource limited, costly, has postoperative morbidity and mortality, and needs lifelong immunosuppression; hence, the search for alternative therapies continues. Recently, understanding of the concept of liver regeneration (LR) has opened new horizons for salvaging the failing liver. In response to injury, LR occurs as a multitier Abbreviations: ACLF, acute on chronic liver failure; AFP, alpha-fetoprotein; AH, alcoholic hepatitis; AKI, acute kidney injury; ALD, alcoholic liver disease; ANOVA, analysis of variance; BMSC, bone marrow stem cells; CI, confidence interval; CTP, Child-Turcotte-Pugh score; DC, decompensated cirrhosis; FACS, fluorescence-activated cell sorting; G-CSF, granulocyte colony-stimulating factor; GH, growth hormone; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; HSCs, hematopoietic stem cells; IGF-1, insulin like growth factor-1; IGFBP, insulin-like growth factor binding protein; ITT, intention to treat; LR, liver regeneration; LSM, liver stiffness measurement; LT, liver transplantation; LVP, large-volume paracentesis; MAC, midarm circumference; MAMC, midarm muscle circumference; MELD, Model for End-Stage Liver Disease score; QOL, quality of life; PVT, portal vein thrombosis; SBP, spontaneous bacterial peritonitis; SF-36v2, short form survey-36 version 2; SGA, subjective global assessment; SMT, standard medical therapy; TFS, transplant-free survival; UNOS, United Network for Organ Sharing; WHO, World Health Organization.
response. Native axin1 hepatocytes, hybrid hepatocytes, hepatic progenitor cells, and bone marrow stem cells (BMSCs) activate and proliferate to restore homeostasis. (2) BMSCs are relatively easy to mobilize and manipulate using colony-stimulating factors and have shown to spontaneously populate the liver and differentiate into hepatic cells. (3) Recently, granulocyte colony-stimulating factor (G-CSF)-induced mobilization of hematopoietic stem cells (HSC) demonstrated improved survival in patients with alcoholic hepatitis and acute on chronic liver failure (ACLF). (4) (5) (6) However, studies in patients with decompensated cirrhosis (DC) are sparse.
Humoral factors like growth hormone (GH) are also essential to sustain LR. (7) GH acts through Janus kinase (JAK)/signal transducer and activator of transcription (STAT) or multikinases to stimulate nuclear factors and cell proliferation. (8) DC is a state of replicative senescence, (9) where exogenous GH may act to augment regeneration. GH has shown to induce LR posthepatectomy, (10) improve nitrogen economy, (11) improve cell-mediated immunity, (12) and reduce hepatic inflammation and fibrosis. (13, 14) Sarcopenia associated with GH resistance can also be mitigated through extraneous GH administration in DC. (15) Here, we evaluated whether multiple courses of G-CSF with or without GH would promote LR, protein anabolism and improve outcomes and QOL in patients with DC.
Materials and Methods
Study design, as outlined in Fig. 1 , was a singlecenter, open-label, randomized, controlled trial conducted at a tertiary center from May 2015 to June 2016. The protocol was approved by an institute ethics committee (reference no.: NK/1950/DM3214), registered at clinical trials (NCT02451033), and adhered to the CONSORT guidelines for randomized, controlled trials, provisions of the Declaration of Helsinki, and good clinical practice guidelines.
PATIENTS
The trial included patients aged 18-80 years with DC (cirrhosis with ascites and/or variceal bleeding and/or encephalopathy and/or jaundice). Diagnosis of cirrhosis was based on history, clinical findings, biochemical tests, imaging, endoscopic findings, and liver biopsy as and when indicated.
(1) Three independent physicians assessed the suitability of the patients for the trial. Etiology of cirrhosis was based on the history of significant alcohol intake, positive viral markers or autoimmune markers, and features of metabolic syndrome. (16) 
EXCLUSION CRITERIA
Patients with ACLF, (17, 18) sepsis, (19) variceal bleed in last 7 days, multiple organ dysfunction syndrome, grade III/IV hepatic encephalopathy (HE), acute kidney injury, spleen size >18 cm, hepatocellular carcinoma (HCC), portal vein thrombosis (PVT), active malignancy, severe cardiac dysfunction, uncontrolled diabetes, retinopathy, recent alcohol abuse in 3 months or ongoing alcoholic hepatitis (AH), hypersensitivity to G-CSF/GH, human immunodeficiency virus positivity, pregnancy, and refusal to consent were excluded.
SCREENING AND RANDOMIZATION
Patients presenting to the department were assessed for eligibility and after obtaining informed consent, those meeting inclusion and exclusion criteria were sequentially numbered and computer generated random number table provided by an independent statistician was used to allocate these patients to one of the
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three arms of therapy. Allocation concealment was done using sequentially numbered opaque sealed envelopes. Group A received injection GH (1 U subcutaneous per day for 12 months) with injection G-CSF (5 lg/kg subcutaneously every 12 hours for 5 days (5) then every 3 monthly for 3 days until 12 months; four cycles) (20) with standard medical therapy (SMT). Group B received injection G-CSF and SMT, and group C received SMT only. SMT included (as per requirement) nutrition with salt-restricted high-protein diet with target calories 35-40 kcal/kg/day, protein 1.5 g/kg/day, and periodic nutrition counseling and reassessment at every visit. Oral rifaximin, lactulose, or lactitol for patients with past or current HE, intravenous albumin (20%) during large-volume paracentesis (LVP; 8 g/L of fluid removed) and diuretics for control of ascites, oral norfloxacin prophylaxis for patients with past spontaneous bacterial peritonitis (SBP) were given. Beta-blockers were given as primary or secondary prophylaxis when indicated and withheld in patients with refractory ascites. Multivitamins, oral calcium, and vitamin D and antibiotics were given as and when indicated. Antivirals were given for hepatitis B virus (HBV) and hepatitis C virus (HCV) as per European Association for the Study of the Liver guidelines. Patients with alcoholic liver disease (ALD) were counseled periodically every month during the follow-up visit for alcohol abstinence. Because all patients had one or more decompensating event, they were eligible for the listing criteria of the LT. However, inability to get LT because of social, financial, or other reasons was the main reason to opt for G-CSF therapy in this study. However, those willing for the LT were subjected to the transplant as per feasibility.
MONITORING
Patients were admitted to the hospital, administered injection G-CSF and GH as per protocol and monitored daily by physical examination and laboratory tests during initial 5 days and later every month for 12 months. Complete blood count, biochemical, and coagulation parameters were assessed on days 0, 3, and 6 and then monthly until the end of study. CD34 1 hematopoietic stem cells (HSCs) were measured as described. (5, 21) Ultrasonography of abdomen was performed at days 0, 3, and 6 to look for the change in spleen size and portal vein flow. Triphasic contrastenhanced computed tomography of abdomen (to detect ascites, HCC, or PVT), measurement of glycated hemoglobin (HbA1c) and alpha-fetoprotein (AFP) were done at baseline and then at 3 monthly intervals. Child-Turcotte Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores were computed at baseline and then at monthly intervals. Need for the LT was assessed by United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network policy for liver allocation. (22) Measurement of liver stiffness was assessed on an empty stomach at baseline and at 12 months using vibrationcontrolled transient elastography, the FibroScan 502 Touch. Those with ascites underwent LVP before the FibroScan. Nutritional assessment was performed at baseline and at 6 and 12 months using modified subjective global assessment (SGA). (23) Average readings of anthropometric variables performed on two occasions and three readings each were analyzed. QOL scores were measured at baseline and at 6 and 12 months using short form survey-36 version 2 (SF-36v2) validated in local language. (24, 25) Questionnaires were filled by patients or allowed to be administered verbally by a research scholar (masked to group allocated to the patient). Data were analyzed by Quality Metric Health Outcomes Scoring Software 4.0 (25) (license number: QM029659). Adverse effects were noted as per World Health Organization (WHO) grading. (26) Infection or sepsis was diagnosed and managed based on existing surviving sepsis guidelines. (19) Frequent telephone calls and structured checklist with a written date for followup given to the subjects ensured the follow-up visits as per protocol. Compliance to the injections was ensured at each follow-up visit by counting the vials of GH consumed over the last month. Outcomes were assessed by a research scholar (A.K.) blinded to the group allocated to the patient.
ESTIMATION OF CD34
1 CELLS IN PERIPHERAL BLOOD Venous blood was collected at baseline and on day 6 in an ethylenediamine tetraacetic acid vacutainer. The total nucleated cell count was performed on an automated hematology analyzer (Sysmex KX-21; Sysmex America, Inc., Mundelein, IL). For mononuclear cell estimation, 10 mL of blood was layered on 5-mL of Ficoll-Hypaque in a 15-mL Tarson tube (Tarson, Kolkata, India). This tube was centrifuged for 10 minutes at 233g (Multipurpose centrifuge Combi-541R; Hanil Science Industrial Co. Ltd, Gwangju, Korea). After centrifugation, the layer containing the mononuclear cells (Buffy coat layer) was isolated.
Two flow tubes (5 mL) were taken and labeled as test and negative control. A volume of 20 lL of anti-CD34 antibody (Becton Dickinson, San Jose, CA) was pipetted into the tube marked as test without touching the side surfaces of the tube. The tube labeled as negative control did not contain any antibodies. Subsequently, 50 lL of well-mixed mononuclear cell sample was added to both tubes. Antibodies and samples were mixed using a vortex mixer and incubated for 15-20 minutes in the dark at room temperature. Following incubation, 1 mL of fluorescence-activated cell sorting (FACS) lysing solution (31; Becton Dickinson) was added to both tubes and left for 10 minutes in the dark at room temperature, and then the samples were centrifuged at 233g for 5 minutes. Following centrifugation, the supernatant was discarded and the cell pellet was suspended in 1 mL of sheath fluid, an isotonic solution for sample preparation for flow cytometry (Becton Dickinson). Samples were again centrifuged at 233g for 5 minutes. Following centrifugation, the supernatant was discarded and the cell pellet was resuspended in 500 lL of sheath fluid for flow cytometric analysis (FACS Aria II Sorp, Becton Dickinson). Data were captured and analyzed according to the International Society of Hematotherapy and Graft Engineering guidelines. (21) 
ENDPOINTS
The primary endpoint was TFS at 12 months. Those patients lost to follow-up or withdrawn from the study were censored during the survival analysis. Secondary endpoints included mobilization of CD34 
SAMPLE-SIZE CALCULATION
The initial sample-size estimation was based on the 12-month survival estimates of 60% in DC (1) and effect difference of at least 25% with G-CSF therapy. (4) (5) (6) Fifty patients in each arm were required [(1-a: 95% confidence interval), power (1-b: 80%), and 10% dropouts]. Later, based on a recent study (27) and assuming 12-month survival of 69% with G-CSF and 27% with SMT in DC, 19 patients in each arm were required [(1-a: 95% confidence interval) and power (1-b: 80%)]. Therefore, assuming a 10% dropout rate, a minimum of 21 patients were recruited in each group to detect a difference between SMT and G-CSF with or without GH therapy.
STATISTICAL ANALYSIS
The analysis was carried out on intention-to-treat (ITT) basis, using Statistical Package for Social Sciences (version 19.0 for Windows; SPSS Inc., Chicago, IL). Data were represented as mean (SD) and median (range) for quantitative variables and number (frequency/proportions) for qualitative variables. Normality was checked by Kolmogorov-Smirnov and Shapiro-Wilk tests. Proportions were compared using chi-square test (Fisher's exact test when applicable) and McNemar test or Cochrane Q test (for unpaired or paired data, respectively). Paired t test and Wilcoxon signed-ranks tests (for normally distributed and skewed data, respectively) were used to compare paired numerical data over two time points. Analysis of variance (ANOVA) and Kruskal-Wallis ANOVA (for normally distributed and skewed data, respectively) were used to compare numerical data between three groups with subsequent post-hoc analysis using Bonferroni correction or pair-wise comparisons using Mann-Whitney U test, respectively. Repeated-measures ANOVA or Friedman's test (for normally distributed and skewed data, respectively) were used to compare paired numerical data over various time intervals with subsequent post-hoc analysis using Bonferroni correction or pair-wise comparisons using Wilcoxon signed-ranks tests. Survival analysis was done by Kaplan-Meier method, and the log-rank test was used to compare between the groups. Cox proportional regression analysis was done to compute and compare hazard ratios of mortality between the groups. Logistic regression analysis was conducted to evaluate the impact of variables on the outcomes of interest. All statistical tests were two-sided and performed at a significance level of a 5 0.05 and adjusted to 0.016 for post-hoc tests.
Results

PATIENTS
Of 500 patients with cirrhosis screened, 23 were allocated to group A, 21 to group B, and 21 to group C. All patients were followed up for 12 months or until the time of their death or LT. All patients (except 1 patient in group A) remained alcohol abstinent and none had presentation compatible with AH during the study. The three groups were well matched with regard to their baseline characteristics and treatment received for the etiology and complications of cirrhosis except for poor QOL scores in groups A and B as compared to group C in the domains of general health, mental health, and mental component summary (Table 1 and Supporting Table  S1 ). The majority of patients (52 of 65; 80.0%) had the history of more than one decompensation at baseline. The type and numbers of decompensation in the three groups were also comparable at baseline. At 12 months, 17% of patients died, 6% were lost to follow-up, 3% were withdrawn from the study, and 1 underwent LT.
ENDPOINTS Primary Endpoint
In group A, of 23 patients, 1 died, 1 underwent LT, 1 was withdrawn because of suspicious small HCC (lesion stable over next 9 months), and 1 was lost to follow-up (Fig. 1) . In group B, of 21 patients, 1 died, 1 was withdrawn because of ongoing alcohol abuse, and 1 was lost to follow-up. In group C, of 21 patients, 9 died and 2 were lost to follow-up. Hazard ratios of 12-month mortality were significantly lower in group A (0.159; 95% confidence interval [CI], 0.034-0.737) and group B (0.085; 95% CI, 0.011-0.678) as compared to group C (P 5 0.019 and 0.020; respectively). The cumulative probability of 12-month TFS was significantly better in groups A and B than in group C (A, 91.3%; B, 95.2%; C, 57.1%; P 5 0.001; Avs.B 5 0.587, Avs.C 5 0.006, and Bvs.C 5 0.003; (Fig. 2) . Estimated mean survival time for groups A, B, and C was 11.5 (95% CI, 10.9-12.1), 11.8 (95% CI, 11.4-12.1), and 8.4 (95% CI, 6.5-10.2) months, respectively. Improvement in survival was evident in group A and group B beginning from 2 months posttherapy (Fig. 2) . As per ITT analysis and considering the worst-case scenario and dropouts as worse outcome, the TFS at 12 months in group A (82.6%) and group B (85.7%) was significantly better than in group C (47.6%; P 5 0.009; Avs.C 5 0.014, Bvs.C 5 0.009, and Avs.B 5 0.778). Mortality in group A was attributed to sepsis, shock, and renal failure (n 5 1); in group B attributed to refractory ascites, sepsis, shock, and renal failure (n 5 1); and in group C attributed to variceal bleeding, sepsis, and shock (n 5 4), sepsis, shock, and renal failure (n 5 2), SBP, pneumonia, sepsis, shock, and renal failure (n 5 2), and disseminated tuberculosis, pneumonia, sepsis, and shock (n 5 1; Supporting Table S2 ).
SECONDARY ENDPOINTS Stem Cell Mobilization
At day 6 of therapy, total leucocyte count and CD34 1 cells increased in groups A and B compared to baseline, with no change in group C (P values <0.001, <0.001, and >0.05, respectively). At day 6, mobilized CD34
1 HSCs were higher in groups A and B compared to group C (P < 0.001; Supporting Table S3 ). There was no change in serum AFP levels during therapy in any arm (Supporting Table S4 ).
Clinical Severity Scores
There was a significant decrease in CTP and MELD scores in groups A and B with an increase in group C at 12 months as compared to baseline (P < 0.05; Table 2 ). Over 12 months, there was a significant reduction in mean CTP and MELD scores in groups A and B as compared to group C (P < 0.001; Table  3 ). Furthermore, mean reduction in severity scores was calculated as % D change at each follow-up from baseline in the three groups [% D change 5 (follow-up day score minus the baseline score) / (baseline score) 3 100]. Overall % D CTP at 12-month follow-up was -25.5% (SD, 12.3) in group A, -24.0% (SD, 11.5) in group B, and 118.0% (SD, 22.6) in group C (P < 0.001). The % D MELD score at 12 months was -25.2% (SD, 12.0) in group A, -24.4 % (SD, 13.4) in group B, and 116.7% (SD, 22.4) in group C (P < 0.001). Improvements in D-CTP and D-MELD were noted in groups A and B compared to group C (P < 0.001; Supporting Fig. S1 ).
Need for LT
Need for LT was reduced over 12 months in groups A and B with no change in group C (P 5 0.002, 0.018, and 0.125, respectively; Table 2 ). At 12 months, 2 of 19 (10%) and 0 of 18 (0%) patients required LT in groups A and B, respectively, as compared to 8 of 10 (80%) in group C (P < 0.001; Table 2 ).
Events of Decompensation
As compared with baseline, the proportion of patients with ascites and encephalopathy at 6 and 12 months were reduced in groups A and B (P < 0.05), whereas no change or increase was noted in group C (Table 2) . At 12 months, the proportions of patients with ascites and encephalopathy were lower in groups A and B as compared to group C (P < 0.001; Table  2 ). Ascites control (complete or partial) was significantly better in groups A and B than in group C (72.7%, 85.7%, and 11.8%, respectively; P < 0.001; Table 4 ). Need for LVP was significantly reduced in groups A and B with no change in group C (P values <0.001, <0.001, and 0.581, respectively; Table 2 ). One patient in group A, 1 patient in group B, and 2 patients in group C bled from varices over 12 months (P 5 0.151 between the groups; Table 2 ). In SGA, adequate nutrition, moderate malnutrition, and severe malnutrition were graded as per modified subjective global assessment. § Repeated measures of ANOVA or Friedman's test to compare parameters at three time points within a group with post-hoc Bonferrroni test or Wilcoxon signed-ranks test was used for pair-wise comparisons. One-way ANOVA was used to compare numerical data and chi-square test (Fisher's exact correction) to compare proportions between three groups with subsequent post-hoc Bonferroni correction or pair-wise comparisons using chi-square test, respectively. k P value <0.05 as significant overall and <0.016 as significant for pair-wise comparisons.
Change in Liver Stiffness
As compared with baseline, liver stiffness was reduced in groups A and B with no change in group C at 12 months (P values <0.001, <0.001, and 0.093, respectively; Table 2 ). At 12 months, there was a reduction in mean LSM in groups A and B as compared to group C (P < 0.001; Table 3 ).
Nutritional Parameters
Among the nutritional parameters over 12 months (Table 5) , there was an improvement in MAC and MAMC and a trend toward improvement in serum albumin in group A (P values <0.001, <0.001, and 0.088, respectively). All three parameters improved in group B (P values <0.001, 0.003, and 0.003, respectively) whereas they worsened or were not changed in group C (P 5 0.007, 0.003, and 0.380, respectively) as compared with baseline. At 12 months, there was an improvement in nutritional status as per SGA in group A (P < 0.001) and group B (P < 0.001) whereas it worsened in group C (P 5 0.028), as compared with baseline. At 12 months, there was an increase in mean MAC and MAMC in groups A and B as compared with group C (P < 0.001; Table 3 ). At 12 months, SGA showed improvement in nutritional status in groups A and B as compared to group C (P < 0.001; Table 3 ).
Sepsis
A higher proportion of patients developed sepsis and required hospitalization in group C as compared to groups A and B (P < 0.05; Supporting Table S2 ). The odds of developing sepsis were reduced by 78% in group A and by 88% in group B as compared to group C (P 5 0.019 and 0.003, respectively; Fig. 3 ). The odds of developing bacterial infection were reduced by 73% in group A and by 82% in group B as compared to group C (P 5 0.040 and 0.014, respectively; Fig. 3 ). The odds of developing SBP infection rather than no   FIG. 3 . Impact of therapies on the development of sepsis, bacterial infections, SBP, and non-SBP infections. This figure demonstrates the reduction in odds of developing sepsis in G-CSF plus GH (group A) and in G-CSF (group B) as compared with SMT (group C; P 5 0.019 and 0.003; respectively). The odds of developing bacterial infection was also reduced by in group A and in group B as compared to group C (P 5 0.040 and 0.014; respectively). The odds of developing SBP infection rather than no infection was reduced in group A and in group B as compared to group C (P 5 0.022 and 0.004; respectively). There was no impact on the odds of developing non-SBP infections rather than no infection in the groups A and B as compared to group C (P 5 0.220 and 0.204; respectively).
infection were reduced by 81% in group A and by 92% in group B as compared to group C (P 5 0.022 and 0.004, respectively). However, there was no impact on the odds of developing non-SBP infections rather than no infection in groups A and B as compared to group C (P 5 0.220 and 0.204, respectively; Fig. 3 ).
QOL Scores
Overall QOL scores improved in groups A and B than in group C at both 6 and 12 months as compared with baseline (P < 0.05; Supporting Table S5 ). The maximum improvement was noted in the initial 6 months in both groups A and B; however, the persistent improvement beyond 6 months was noted across all domains in group A and within social functioning, role emotional, and mental health domains in group B. At 12 months, there was an improvement in mean composite scores of QOL in group A and B as compared to group C (P < 0.001; Table 3 ).
Glycemic Control Adverse Effects
Therapies were well tolerated with no discontinuation of drugs and none had major adverse effects. Adverse effects observed (Supporting Table S7 ) were mild WHO grade I or II. The majority of adverse effects were related to G-CSF and included back pain, fatigue, bone pains, and fever, and with GH were injection-site hypertrophy, discoloration, and mild epistaxis.
Discussion
This study demonstrated mobilization of HSCs and improvement in 12-month TFS with G-CSF with or without GH, as compared to SMT alone. A recent study demonstrated improved 12-month survival (69%) with G-CSF and darbopoetin-alpha therapy for 1 month in DC. (27) In our study, the majority of patients (80%) had more than one decompensation with a median duration of more than 12 months and an expectedly worse 12-month survival. We demonstrated better survival with multiple courses of G-CSF with or without GH compared to short-course G-CSF treatment, as shown by others. (27, 28) The largest study on stem cell transplantation in DC also showed improved survival. (28) In principle, G-CSF-induced mobilized HSCs have shown to home in damaged liver (along stromal-derived factor and C-X-C motif chemokine receptor type 4 gradient) and by transdifferentiation and cellular fusion, supporting hepatic progenitor cell proliferation in a paracrine manner (29) or by direct stimulation of hepatic progenitor cells (30) promote LR. Multiple courses of G-CSF have also shown to induce HSCs expressing multiple hepatocyte markers like albumin, AFP, hepatocyte nuclear factor 4 alpha 1, and cytochrome P450 2B6. (20) A recent study demonstrated improvement in LR using G-CSF and/or plerixafor-mobilized HSCs independent of the extent of mobilization, implying that non-HSCmediated mechanisms may also contribute to LR. (31, 32) The likely improvement in LR induced by G-CSF in our study improved the survival of patients with DC.
GH also contributes to LR through the Foxm1b pathway and increasing cyclin proteins: Cdc25A, Cdc25B, and cyclin B1 and reducing cyclin-dependent kinase p27 by acting on its residual receptors on hepatocytes. (11, 33) Recently, GH has shown to prevent liver injury by inhibiting apoptosis through the hnf6 pathway.
(34) However, we did not find additional benefit of GH in the present study, which may be because of the low dose of GH and small numbers.
Improvement in liver functions, including CTP, MELD, serum albumin, HE, and ascites control, in this study also reflects the outcomes of enhanced LR. Similarly, short-course G-CSF and darbopoetin-alpha have also shown improvements in CTP, MELD, ascites, variceal bleeding, and HE in patients with DC. (27) Also, improvement in nutritional parameters with SMT and G-CSF with or without GH was noted as compared to SMT alone. In past, studies have emphasized the presence of GH resistance and malnutrition in cirrhosis. (35) Short-term administration of GH in cirrhosis has shown an increase in insulin like growth factor-1 (IGF-1), insulin-like growth factor binding protein (IGFBP-3) levels, and improvement in nitrogen economy. (11) GH has also been shown to increase serum prealbumin, transferrin, liver Ki-67 labeling index, and LR. (10) Supraphysiological doses of GH may have the strong effect (33) ; however, the safety of such doses for a long duration is not known. So, in this study, we used the low-dose GH based on the guidelines for treatment of adults with GH deficiency. (36) VERMA, SINGH, ET AL.
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At 12 months, there was an improvement in glycemic control among persons with diabetes in group B (P = 0.028) with no change in groups A and C (P = 0.470 and 0.686, respectively) as compared with baseline (Supporting Table S6 ).
We also demonstrated a reduction in the need for LT in patients who received G-CSF with or without GH as compared to SMT. However, long-term follow-up is required to conclude whether these therapies may avoid LT.
Infections are an important cause of morbidity and mortality in DC possibly attributed to impaired protein kinase B/p38-mitogen-activated protein kinase signaling, neutrophil myeloperoxidase-exocytosis, oxidative burst, (37) and immune dysfunction. We demonstrated reduced infections/sepsis and rate of hospitalization in patients receiving G-CSF with or without GH as compared to SMT. G-CSF has also shown to improve neutrophil functions, oxidative burst, phagocytic activity, (38) and intrahepatic dendritic cells and T-regulatory cells in liver cirrhosis. (39) It has also been shown to reduce sepsis and septic shock in patients with DC and ACLF. (4, 27) Interestingly, we also noted reduction in mean liver stiffness over 12 months with use of G-CSF with or without GH as compared to SMT. Recently, GH and IGF-1 has shown to induce senescence of hepatic stellate cells and limit fibrosis by a p53-dependent manner. (13) G-CSF-mobilized HSC and BMSC transfusions in cirrhosis have also shown to improve fibrosis by reducing inflammation and improving stellate cell functions. (31, 40) They have shown to decrease portal hypertension by endothelial progenitor cell recruitment and restoring abnormal vasculature. (31, 40, 41) Recently, a study also demonstrated the reduction in hepatic venous pressure gradient with G-CSF therapy in DC. (27) We demonstrated poor QOL scores in patients with DC, explainable by multiple decompensating events and long duration of illness. Also, a significant improvement was noted in QOL scores in patients receiving G-CSF with or without GH with no change in patients on SMT alone, which was likely attributed to improved clinical outcomes in the former. Others have also shown improvement in QOL after HSC transfusions in cirrhosis. (28, 41) Intriguingly, glycemic control improved in patients on G-CSF, possibly
Multiple courses of G-CSF with or without GH were well tolerated without any drug discontinuation consistent with the available literature. (20, 27, 44) This study demonstrated the safety and efficacy of multiple courses of G-CSF with or without GH in patients with DC. Limitations include open-label trial, unclear optimal dosing of the medications, and no liver biopsy to demonstrate homing of HSCs. The study population was relatively young (mean, 51 years) and males constituted 80%, which may question the generalizability of this study. However, similar demographics had been reported by D'Amico et al. with median age 54 years (range, 44-67) and the majority (67%) being males. (1) We excluded patients with ongoing ACLF, sepsis, recent HE, recent variceal bleeding, acute kidney injury (AKI), and HCC, which constitutes the dominant population of DC admitted to the hospital. However, as discussed earlier, our group had an expectedly worse 12-month survival and needed special attention. Moreover, other studies have also excluded the similar group of patients (16, 27) and some have already reported improved outcomes with G-CSF in patients with ACLF. (4) (5) (6) Multiple courses of G-CSF with or without GH were safe and improved 12-month TFS, mobilized HSCs, and improved disease severity scores, nutrition, fibrosis, QOL, ascites control, reduced infections, and need for LT in patients with DC. The use of GH did not have any additional benefit. Further multicentric trials on optimal dose and duration of liver regenerative therapies are required.
attributed to improvement in pancreatic beta-cell functions. HSC transplantation in persons with diabetes has shown to recruit tolerogenic dendritic cells and T-regulatory cells and improve glycemic control. (42, 43) Hence, the impact of G-CSF on glycemic control needs to be explored in larger studies.
